Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
antagonist of serotonin and dopamine receptors
|
| gptkbp:affects |
metabolic syndrome
cardiovascular issues hyperlipidemia diabetes risk tardive dyskinesia |
| gptkbp:approves |
gptkb:legislation
gptkb:1997 gptkb:United_States |
| gptkbp:brand |
gptkb:Seroquel_XR
gptkb:Seroquel Xeroquel |
| gptkbp:category |
gptkb:C
|
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to quetiapine |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:dosage_form |
gptkb:tablet
extended-release tablet 300-800 mg per day |
| https://www.w3.org/2000/01/rdf-schema#label |
quetiapine
|
| gptkbp:ingredients |
C21 H25 N3 O2 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
N05 A H04
|
| gptkbp:is_available_in |
tablets
oral solution extended-release tablets |
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_used_for |
schizophrenia
bipolar disorder major depressive disorder |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
6 hours
12 hours for extended-release |
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:2000
|
| gptkbp:pharmacokinetics |
highly protein-bound
metabolized by liver |
| gptkbp:side_effect |
dizziness
drowsiness constipation dry mouth weight gain sedation orthostatic hypotension |
| gptkbp:type_of |
111974-72-2
|
| gptkbp:bfsParent |
gptkb:Seroquel
|
| gptkbp:bfsLayer |
4
|